Key update sent Voyager Therapeutics (VYGR) stock go bullish in the After-hours

Voyager Therapeutics (Nasdaq: VYGR) shares dropped -14.73% to $7.7 in the After-market ‎session on Tuesday after the U.S. Neurocrine Biosciences (Nasdaq: NBIX) has been told by ‎the Food and Drug Administration (FDA) that it has put a clinical hold on the NBIb-1817b ‎clinical trial RESTORE-1 (VY-AADC). It was previously disclosed that sites participating in ‎RESTORE-1 had not been screening, enrolling, or dosing patients due to the ongoing COVID-‎‎19 pandemic and more recently, the independent Data Safety Monitoring Board’s request to ‎pause the study in order to collect additional data. The DSMB sought further patient level ‎data from the study and is now preparing to revisit this data at the beginning of 2021. The ‎clinical retention follows the submission of an IND Safety Report by Neurocrine Biosciences ‎pertaining to the observation of MRI anomalies in certain members of the RESTORE-1 trial. ‎At present, the clinical effects of this finding are uncertain and are being assessed.‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

‎RESTORE-1 is a phase 2 clinical trial of the intracerebral AAV-based investigational gene ‎therapy NBIb-1817 (VY-AADC) in progress for Parkinson’s disease treatment. As well as the ‎research investigators and national and local ethics boards, the RESTORE-1 DSMB was told ‎of the therapeutic keeping. In order to define the next steps for the RESTORE-1 clinical trial, ‎Neurocrine Biosciences and Voyager will collaborate closely with the FDA and the DSMB.‎

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Read More

Most Popular

Related posts